Manufacturer Supply Darunavir Related Products:
Darunavir CAS 206361-99-1
Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Chemical Name | (2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane |
| Synonyms | (2S,3S)-3-(Boc-Amino)-1,2-Epoxy-4-Phenylbutane; (2S,3S)-3-(tert-Butoxycarbonylamino)-1,2-epoxy-4-phenylbutane; Darunavir Intermediate |
| CAS Number | 98737-29-2 |
| CAT Number | RF-PI286 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C15H21NO3 |
| Molecular Weight | 263.33 |
| Solubility | Insoluble in Water. Soluble in Methanol, Chloroform |
| Shipping Condition | Shipped Under Ambient Temperature |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification (HPLC) | The Identification is Confirmed by HPLC |
| Melting Point | 123.0~128.0℃ |
| Moisture (K.F) | ≤0.50% |
| Residue on Ignition | ≤0.20% |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Chlorohydrin (HPLC) | ≤0.20% |
| Chloromethyl Ketone | ≤0.10% |
| Other Single Impurity | ≤0.20% |
| Total Impurities | ≤1.0% |
| Chiral Impurity | ≤0.30% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Darunavir (CAS 206361-99-1) HIV-1 Protease Inhibitor |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane (CAS: 98737-29-2) with high quality, an intermediate typically in the synthesis of Darunavir (CAS 206361-99-1) and Darunavir Ethanolate (CAS 635728-49-3).
Darunavir (CAS 206361-99-1) is a new kind of non peptide anti retroviral protease inhibitors in AIDS therapy. It is first developed by the Johnson pharmaceutical Iceland branch, Tibotec. It is of the highest bioavailability in the 6 protease inhibitors (saquinavir, ritonavirvir, indinavir, naphthalene nelfinavir, amprenavir and ABT378/r). It acts by blocking the formation of new and mature virus particles from the surface of the infected host cells and inhibiting the virus's protease. When the product is used for a long time, it usually can reduce the HIV virus vector in blood, increase the count of CD4 cells, reduce the chance of HIV infection, improve the quality of life and prolong life. It is suitable for adults who are infected with the HIV virus but have no effect on the use of existing antiretroviral drugs. The drug must be combined with the use of low doses of ritonavir or other antiretroviral agents, in order to improve the efficacy.